Get the Stockscreener App
49.57
1.31%
0.64
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $49.57, with a volume of 10.08M.
It is up +1.31% in the last 24 hours and down -16.88% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$48.93
Open:
$49.3
24h Volume:
10.08M
Relative Volume:
0.48
Market Cap:
$220.42B
Revenue:
$46.77B
Net Income/Loss:
$15.45B
P/E Ratio:
14.29
EPS:
3.468
Net Cash Flow:
$4.40B
1W Performance:
+4.05%
1M Performance:
-16.88%
6M Performance:
-2.61%
1Y Performance:
-37.12%
1-Day Range:
$49.20
$49.84
1-Week Range:
$48.08
$51.09
52-Week Range:
$43.08
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
49.57 | 217.58B | 46.77B | 15.45B | 4.40B | 3.468 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Upgrade | Jefferies | Underperform → Hold |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens - Sahm
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 - The Motley Fool
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside - Sahm
Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending - Finviz
Jim Cramer on Novo Nordisk: "It Seems Eli Lilly's Eating Their Lunch" - Finviz
Novo Nordisk Warning Tests Valuation As Pricing And Competition Intensify - Sahm
Ozempic Maker Novo Nordisk Flags Declining Sales In 2026 - Sahm
Novo Nordisk Faces a Sales Decline in 2026, But Its Portfolio and Pipeline Provide Long-Term Growth - Morningstar
Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? - Finviz
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Novo Nordisk ADR earnings beat by $0.10, revenue topped estimates - Investing.com South Africa
Novo Nordisk's U.S. listing drops significantly after earnings report - medwatch.com
Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz
Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy" - Finviz
Is Novo Nordisk Stock a Bargain Right Now? - Finviz
BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures - Finviz
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? - Finviz
Novo Nordisk Oral Wegovy Launch Reshapes Obesity Access And Valuation Outlook - Sahm
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? - Finviz
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? - Finviz
5 Stocks To Keep an Eye On in 2026, According to Experts - AOL.com
Novo Nordisk’s Wegovy Pill And Akero Deal Reframe Obesity Growth Story - Sahm
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):